122 related articles for article (PubMed ID: 22850367)
1. Letter by Moody et al regarding article "Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction".
Moody WE; Edwards NC; Townend JN
Circulation; 2012 Jul; 126(5):e62; author reply e64-5. PubMed ID: 22850367
[No Abstract] [Full Text] [Related]
2. Letter by Romanelli et al regarding article, "Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction".
Romanelli G; Mottram PM; Peverill RE
Circulation; 2012 Jul; 126(5):e63; author reply e64-5. PubMed ID: 22850368
[No Abstract] [Full Text] [Related]
3. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction.
Zile MR; Gottdiener JS; Hetzel SJ; McMurray JJ; Komajda M; McKelvie R; Baicu CF; Massie BM; Carson PE;
Circulation; 2011 Dec; 124(23):2491-501. PubMed ID: 22064591
[TBL] [Abstract][Full Text] [Related]
4. Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease.
Packer M
Circ Heart Fail; 2011 Sep; 4(5):538-40. PubMed ID: 21934089
[No Abstract] [Full Text] [Related]
5. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
[TBL] [Abstract][Full Text] [Related]
6. Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west.
Rossignol P; Zannad F
Circulation; 2015 Jan; 131(1):7-10. PubMed ID: 25406307
[No Abstract] [Full Text] [Related]
7. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy.
Cardiovasc J Afr; 2008; 19(6):337-8, discussion 339. PubMed ID: 19104736
[No Abstract] [Full Text] [Related]
8. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
[TBL] [Abstract][Full Text] [Related]
9. Irbesartan for heart failure with preserved ejection fraction.
Tomoda H
N Engl J Med; 2009 Mar; 360(12):1257-8; author reply 1258-9. PubMed ID: 19301449
[No Abstract] [Full Text] [Related]
10. Irbesartan for heart failure with preserved ejection fraction.
Amato JL; Amato JL
N Engl J Med; 2009 Mar; 360(12):1256-7; author reply 1258-9. PubMed ID: 19297582
[No Abstract] [Full Text] [Related]
11. Still at the drawing board: improving quality of life in heart failure.
Lewis EF
Circ Heart Fail; 2012 Mar; 5(2):137-9. PubMed ID: 22438518
[No Abstract] [Full Text] [Related]
12. Irbesartan for heart failure with preserved ejection fraction.
Schillaci G; Pucci G; Pirro M
N Engl J Med; 2009 Mar; 360(12):1258; author reply 1258-9. PubMed ID: 19301450
[No Abstract] [Full Text] [Related]
13. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
Komajda M; Carson PE; Hetzel S; McKelvie R; McMurray J; Ptaszynska A; Zile MR; Demets D; Massie BM
Circ Heart Fail; 2011 Jan; 4(1):27-35. PubMed ID: 21068341
[TBL] [Abstract][Full Text] [Related]
14. Irbesartan for heart failure with preserved ejection fraction.
Ghali JK
N Engl J Med; 2009 Mar; 360(12):1257; author reply 1258-9. PubMed ID: 19301448
[No Abstract] [Full Text] [Related]
15. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
Campbell RT; Jhund PS; Castagno D; Hawkins NM; Petrie MC; McMurray JJ
J Am Coll Cardiol; 2012 Dec; 60(23):2349-56. PubMed ID: 23141494
[TBL] [Abstract][Full Text] [Related]
16. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
[TBL] [Abstract][Full Text] [Related]
17. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
Lam CS; Carson PE; Anand IS; Rector TS; Kuskowski M; Komajda M; McKelvie RS; McMurray JJ; Zile MR; Massie BM; Kitzman DW
Circ Heart Fail; 2012 Sep; 5(5):571-8. PubMed ID: 22887722
[TBL] [Abstract][Full Text] [Related]
18. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
Gandhi PU; Chow SL; Rector TS; Krum H; Gaggin HK; McMurray JJ; Zile MR; Komajda M; McKelvie RS; Carson PE; Januzzi JL; Anand IS
J Card Fail; 2017 Jan; 23(1):20-28. PubMed ID: 27317843
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.
Cannon JA; Shen L; Jhund PS; Anand IS; Komajda M; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2016 Aug; 18(8):1021-31. PubMed ID: 27194023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
